Application 125399
- Type
- BLA
- Sponsor
- SEATTLE GENETICS
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 125399 | Adcetris | brentuximab vedotin | 351(a) | Rx | 2021-02-01 |
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | ADCETRIS | BRENTUXIMAB VEDOTIN | INJECTABLE; INJECTION | 50MG/VIAL | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ADCETRIS | BRENTUXIMAB VEDOTIN | SEAGEN INC. | 3904f8dd-1aef-3490-e48f-bd55f32ed67f | 2025-11-11 | Boxed warning, Warnings, Adverse reactions | ADCETRIS BRENTUXIMAB VEDOTIN |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.